FDA Unable to Approve Narsoplimab for HSCT-TMA Without More Data
Cardiovascular Disease General Hematologic Disorders Leukemias/lymphomas/ And Other Hematologic Cancers News Thromboembolic Disorders

FDA Unable to Approve Narsoplimab for HSCT-TMA Without More Data

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Omeros Corporation regarding the Biologics License Application (BLA) for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).…